EN DE
Watch Kaken Pharmaceutical Co. Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Kaken Pharmaceutical Co. Ltd (KKPCF) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of Kaken Pharmaceutical Co. Ltd stock $7.86, price $23.97, that is 67.2% below the price, quality 47 out of 100. Rating: strongly overvalued. Calculated from audited financials with 10 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Based in Japan

KP Kaken Pharmaceutical Co. Ltd logo Some data Nov 16, 2026

Kaken Pharmaceutical Co. Ltd

KKPCF · US

Far too expensive (fair value 67% below the price) and weak company.

Get notified free when this changes
Solidly profitable · 11.7% net margin (TTM) 
Ranks above peers (8/11) 
Last quarter vs. a year ago: revenue +60%, profit +30%. 
Quality 47/100 
Moderate moat 50/100 · thin data
Some data 
Fair value $7.86 · Strongly overvalued 
Weak Growth (revenue 5y +0.6 %/yr in JPY) 
Negative free cash flow 
5.0% dividend yield · Pays more than it earns
Price via web search⚠ Thinly traded
Watch Kaken Pharmaceutical Co. Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$29.50 $18.05 Fair Value $7.86 May 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range $18.05 – $29.50 · fair‑value band $5.89 – $9.82 · the $23.97 price screens above the $7.86 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow Kaken Pharmaceutical Co. in your weekly email

Every Wednesday you see whether Kaken Pharmaceutical Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally.

Show moreShow less

The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surgery and gynecology to reduce complications from post-operative adhesions.

It also provides agrochemicals and animal health products, including Polyoxins, that are used as fungicides; Pentoxazone and Metamifop rice herbicides; Salinomycin, an anti-coccidial feed additive for chickens; and Uroston, a urinary stone dissolution and elimination acceleration agent for cattle.

In addition, the company is developing KMW-1 for the removal of eschar; KAR, which is in phase III clinical trial for the treatment of head lice; KP-001, which is in phase III clinical trial for the treatment of refractory vascular malformations; Seladelpar that is in phase III clinical trial for primary biliary cholangitis; KP-483, which is in phase I clinical trial for the treatment of solid tumors; NM26-2198 that is in phase I clinical trial for the treatment of atopic dermatitis; KP-910, which is in phase I clinical trial for peripheral neuropathic pain; and Tildacerfont, which is in phase I clinical trial for congenital adrenal hyperplasia.

Further, it is involved in the rental of Bunkyo Green Court. The company has a collaboration and licensing agreement with Alumis Inc. to develop, manufacture, and commercialize ESK-001, a selective oral tyrosine kinase 2 (TYK2) inhibitor for dermatology indications in Japan.

Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.

Stock analysis

Kaken Pharmaceutical Co. Ltd (KKPCF) currently trades at $23.97, while our model-based Fair Value estimate is $7.86, 67% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Economic Profit group reads highest at a median of $16.02 per share, and 1 of the 10 models we run sit above the $23.97 price.

Bear case: the Earnings-Based group reads lowest at $2.97, and 9 of the 10 models stay below the price. Data coverage for this calculation is medium.

Scenario range: $5.89 (bear) to $9.82 (bull), the price of $23.97 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Kaken Pharmaceutical Co. Ltd reported revenue of ¥77.4B in FY2026 versus ¥76.0B in FY2022, a compound +0.4%/yr. Reported net income was ¥2.2B in FY2026, compounding −31.1%/yr from FY2022.

Key figures

Market cap $985M Small · EPS (TTM) $−0.7000 · Dividend yield 5.0% · Net margin 2.8% · Return on equity 6.9% · Return on assets (EBIT) 6.2% (5-year average) · Operating margin 36.2% · Revenue (TTM) ¥88.2B.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 13% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −67%, KKPCF screens richer than that median.

Fair Value models

Bear $5.89 Fair Value $7.86 Bull $9.82
Price $23.97 · Downside -67.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income $15.60 $16.02 $16.82 76
Gordon GGM $9.27 $10.07 $11.28 69
Graham-Dodd $2.43 $2.97 $3.35 67
All 10 models by family
Earnings-Based
Graham-Dodd $2.43 $2.97 $3.35 67
Dividend Discount
Gordon GGM $9.27 $10.07 $11.28 69
DDM Multi-Stage $9.27 $11.34 $14.14 67
Multiples
P/E Multiple $5.91 $7.87 $9.84 63
P/S Multiple $4.56 $6.09 $7.61 58
P/B Multiple $69.49 $92.66 $115.82 55
EV/EBITDA $11.08 $12.49 $13.91 64
Asset-Based
NCAV (Graham) $6.99 $10.59 $13.24 52
Economic Profit
Residual Income $15.60 $16.02 $16.82 76
Growth Earnings
Growth-Adj P/E $4.16 $5.95 $7.73 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 47/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 26
How much profit the company makes from its sales and capital
Quality Growth 4
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 81
Debt, balance sheet and risk of trouble
Investment 87
Does it invest with discipline instead of growing at any price?
Low Volatility 87
How calm the share price moves, does not count
Price momentum 41
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 49
Distance to the 52-week high, does not count
New shares 84
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 25/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−17.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.6%
Start year 2021 (pandemic). Over 10 years: −3.4% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.2%
What shareholders gained per year (last 5 years), in JPY ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in JPY: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−25.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year−30.3%
Dividend (yield on the price)5.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−30.3% vs −19.7%, slowing
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.24% → −1%
Pace: the 5-year rate starts in 2021 (pandemic)

KKPCF screens overvalued: fair value 67% below the price. Compare with Merck KGaA →

Compare Kaken Pharmaceutical Co. Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks

Beats the industry median on 8/11 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 47 · Below median
Fair Value upside −67.2% · Bottom 25%
Profitability
Return on equity (12 months) 6.9% · Above median
Return on assets 1.2% · Below median
Net margin (12 months) 11.7% · Above median
Operating margin (12 months) 36.2% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 59.8% · Top 25%
Dividend yield (12 months) 5.0% · Top 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 0.97× · Cheapest 25%
P/S (12 months) 1.64× · Cheaper than median
EV/EBITDA 8.3× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 19
FUTURE (revenue growth)100 · sector 28
PAST (return on equity)27 · sector 26
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)100 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $84.39 $113.53 +35% vs KKPCF
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.02 ¥53.04 +10% vs KKPCF
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,868 ₹1,983 +6% vs KKPCF
Haleon plc HLN $9.20 $8.47 −8% vs KKPCF
Merck KGaA MRK €149.70 €108.83 −27% vs KKPCF
Galderma Group GALD CHF 191.00 CHF 112.46 −41% vs KKPCF
Takeda Pharmaceutical Company TAK $21.59 $11.23 −48% vs KKPCF
Teva Pharmaceutical Industries Limited TEVA $42.57 $20.74 −51% vs KKPCF
Sandoz Group SDZ CHF 84.60 CHF 40.54 −52% vs KKPCF
Divi's Laboratories Limited DIVISLAB ₹11,080 ₹1,567 −86% vs KKPCF

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Kaken Pharmaceutical Co. Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Kaken Pharmaceutical Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/KKPCF

Frequently asked questions

Is Kaken Pharmaceutical Co. Ltd (KKPCF) overvalued or undervalued?
As of Nov 16, 2026, our model estimates a fair value of $7.86 versus a price of $23.97, about 67% lower (overvalued).
What is the fair value of KKPCF?
Our model-based fair value for Kaken Pharmaceutical Co. Ltd is $7.86 (as of Nov 16, 2026), built from audited fundamentals. The current price: $23.97.
What is the quality score of KKPCF?
Kaken Pharmaceutical Co. Ltd has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Kaken Pharmaceutical Co. Ltd (KKPCF)?
Our model-based price target is the fair value of $7.86 (as of Nov 16, 2026) from 10 valuation models. Cautious scenario $5.89, optimistic scenario $9.82. It is a calculation from audited fundamentals, not an analyst target.
What is the Kaken Pharmaceutical Co. Ltd stock forecast for 2026?
Our models put fair value at $7.86, about 67% lower versus a price of $23.97 (overvalued). Cautious scenario $5.89, optimistic scenario $9.82. The calculation is refreshed regularly with new filings.
What is the revenue of Kaken Pharmaceutical Co. Ltd (KKPCF)?
Kaken Pharmaceutical Co. Ltd reported trailing-twelve-month revenue of about ¥88.2B (latest available figure, as of Nov 16, 2026).
Does Kaken Pharmaceutical Co. Ltd pay a dividend?
Kaken Pharmaceutical Co. Ltd currently shows a dividend yield of 4.98% relative to its recent price (as of Nov 16, 2026).
How much is the dividend of Kaken Pharmaceutical Co. Ltd (KKPCF) and when is the ex-dividend date?
Kaken Pharmaceutical Co. Ltd pays a dividend of $1.19 per share a year, a dividend yield of 5.0%. The next ex-dividend date is Mar 31, 2027. A dividend has been paid every year since at least 2009. Our assessment: Pays more than it earns. The company pays out more in dividends than it earns, and free cash flow clearly does not cover the dividend either. It may need to be cut unless profits recover.
What is the intrinsic value of Kaken Pharmaceutical Co. Ltd (KKPCF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Kaken Pharmaceutical Co. Ltd it is $7.86 per share (as of Nov 16, 2026), against a price of $23.97. It is the blended result of 10 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Kaken Pharmaceutical Co. Ltd stock overvalued or undervalued in 2026?
As of Nov 16, 2026, KKPCF trades above its calculated fair value: price $23.97, fair value $7.86, a gap of about −67% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of KKPCF?
No. The price is what the market pays today ($23.97); the fair value is what the company's own numbers justify ($7.86). For Kaken Pharmaceutical Co. Ltd the two are $16.11 per share apart. That gap is exactly why we show both numbers side by side.
How much is Kaken Pharmaceutical Co. Ltd worth?
The market values Kaken Pharmaceutical Co. Ltd at about $985M (market capitalisation, as of Nov 16, 2026). Per share that is $23.97; our models calculate a fair value of $7.86 per share.
What do the bullish and bearish scenarios say about KKPCF?
Our models span a range for Kaken Pharmaceutical Co. Ltd: cautious scenario $5.89, base $7.86, optimistic $9.82 per share (as of Nov 16, 2026, price $23.97). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Kaken Pharmaceutical Co. Ltd (KKPCF)?
Balance-sheet figures for Kaken Pharmaceutical Co. Ltd (as of Nov 16, 2026): return on equity 6.9%. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is KKPCF from its 52-week high?
Kaken Pharmaceutical Co. Ltd trades at $23.97, about 13% below its 52-week high of $27.47 and 4% above the low of $23.10 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of $7.86 is for.
Which stocks are comparable to Kaken Pharmaceutical Co. Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Kaken Pharmaceutical Co. Ltd stock attractive at the current price?
The data as of Nov 16, 2026: price $23.97, calculated fair value $7.86 (−67%), Quality Score 47/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of KKPCF calculated?
We run Kaken Pharmaceutical Co. Ltd through 10 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $7.86 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Kaken Pharmaceutical Co. Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Kaken Pharmaceutical Co. Ltd (KKPCF)?
The closing price on Nov 13, 2026 was $23.97. Our model-based fair value is $7.86, about 67% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Kaken Pharmaceutical Co. Ltd right now?
The price sits above even our optimistic bull case ($9.82). The favourable scenario is already priced in. Weak quality (47/100) and above fair value at the same time, the margin of safety is missing on both counts.
Where does the earnings growth of Kaken Pharmaceutical Co. Ltd (KKPCF) come from?
Earnings per share at Kaken Pharmaceutical Co. Ltd fell 4.9 % a year from 2015 to 2026. Broken into its drivers: revenue per share −1.4 %, EBIT margin −5.0 %, tax rate +1.7 %, residual (interest, one-offs) −0.3 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Kaken Pharmaceutical Co. Ltd

How large is the market capitalisation of Kaken Pharmaceutical Co. Ltd (KKPCF)?
The market capitalisation of Kaken Pharmaceutical Co. Ltd is $985M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Kaken Pharmaceutical Co. Ltd (KKPCF)?
Earnings per share at Kaken Pharmaceutical Co. Ltd are $−0.7000. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Kaken Pharmaceutical Co. Ltd (KKPCF)?
The dividend yield of Kaken Pharmaceutical Co. Ltd is 5.0%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Kaken Pharmaceutical Co. Ltd (KKPCF)?
The net margin of Kaken Pharmaceutical Co. Ltd is 2.8% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Kaken Pharmaceutical Co. Ltd (KKPCF)?
The return on equity (ROE) of Kaken Pharmaceutical Co. Ltd is 6.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Kaken Pharmaceutical Co. Ltd (KKPCF)?
On an EBIT basis the return on assets of Kaken Pharmaceutical Co. Ltd is 6.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Kaken Pharmaceutical Co. Ltd (KKPCF)?
The operating margin of Kaken Pharmaceutical Co. Ltd is 36.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Kaken Pharmaceutical Co. Ltd (KKPCF)?
Revenue at Kaken Pharmaceutical Co. Ltd is growing 59.8% versus a year earlier (3y avg +2.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Kaken Pharmaceutical Co. Ltd (KKPCF)?
Earnings per share at Kaken Pharmaceutical Co. Ltd are growing 30.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Kaken Pharmaceutical Co. Ltd (KKPCF) generate?
The free cash flow of Kaken Pharmaceutical Co. Ltd is −¥14.2B (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Kaken Pharmaceutical Co. Ltd (KKPCF) hold?
Kaken Pharmaceutical Co. Ltd holds more cash than debt, ¥41.1B net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Kaken Pharmaceutical Co. Ltd in the live analysis

One click puts Kaken Pharmaceutical Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.